WO2016044272A1 - Procédés de conservation de la force musculaire au cours d'une période d'inactivité musculaire par administration de bêta-hydroxy-bêta-méthylbutyrate et d'un extrait de thé vert - Google Patents

Procédés de conservation de la force musculaire au cours d'une période d'inactivité musculaire par administration de bêta-hydroxy-bêta-méthylbutyrate et d'un extrait de thé vert Download PDF

Info

Publication number
WO2016044272A1
WO2016044272A1 PCT/US2015/050179 US2015050179W WO2016044272A1 WO 2016044272 A1 WO2016044272 A1 WO 2016044272A1 US 2015050179 W US2015050179 W US 2015050179W WO 2016044272 A1 WO2016044272 A1 WO 2016044272A1
Authority
WO
WIPO (PCT)
Prior art keywords
period
muscle
composition
hours
oil
Prior art date
Application number
PCT/US2015/050179
Other languages
English (en)
Inventor
Suzette Pereira
Neile Edens
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2016044272A1 publication Critical patent/WO2016044272A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Definitions

  • the present disclosure relates to methods of preserving muscle strength in a subject during a period of muscle disuse. Particularly, the present disclosure relates to the use of compositions comprising B-hydroxy-B-methylbutyrate and green tea extract to preserve muscle strength in such subjects during a period of muscle disuse and, optionally, during a period of muscle recovery.
  • Prolonged muscle disuse can lead to loss of muscle tissue and reduced muscle strength.
  • Muscle disuse can be due to immobilization (e.g., casting), injury, disease, bed rest, hospitalization, extended air travel, weightlessness, and the like.
  • the loss of muscle tissue and muscle strength is generally exacerbated by aging. This loss of muscle tissue and muscle strength may impair a subject's mobility, which discourages physical activity and leads to even further loss of muscle tissue.
  • a relatively short period of muscle disuse may begin a downward spiral of muscle loss, increased dependence, and lowered quality of life.
  • Muscle strength is preserved by administering a composition containing B-hydroxy-B-methylbutyrate (HMB) and green tea extract (GTE) to the subject.
  • HMB B-hydroxy-B-methylbutyrate
  • GTE green tea extract
  • methods of preserving muscle strength of a subject during a period of muscle disuse are disclosed.
  • the period of muscle disuse is at least about 4 hours.
  • the period of muscle disuse is from about 24 hours to about 36 months.
  • the methods include administering a composition comprising an effective amount of HMB and an effective amount of GTE to the subject during at least a portion of the period of muscle disuse.
  • This embodiment includes a composition for use in preserving muscle strength of a subject during a period of muscle disuse, wherein the composition comprises an effective amount of green tea extract, and an effective amount of B-hydroxy-B-methylbutyrate and where the composition is administered during at least a portion of the period of muscle disuse, and the period of muscle disuse is at least 4 hours.
  • This embodiment also includes use of a composition comprising an effective amount of green tea extract and an effective amount of B-hydroxy-B-methylbutyrate for the manufacture of a medicament for preserving muscle strength of a subject during a period of muscle disuse wherein the composition is administered during at least a portion of the period of muscle disuse and the period of muscle disuse is at least 4 hours.
  • methods of preserving muscle strength of a subject during a period of muscle disuse and a subsequent period of muscle recovery are disclosed.
  • the period of muscle disuse and the period of muscle recovery are each at least about 4 hours.
  • the methods include administering a composition comprising an effective amount of HMB and an effective amount of GTE to the subject during at least a portion of both the period of muscle disuse and the period of muscle recovery.
  • This embodiment also includes a composition for use in preserving muscle strength of a subject during a period of muscle disuse and a period of muscle recovery following the period of muscle disuse, wherein the composition comprises an effective amount of green tea extract, and an effective amount of B-hydroxy-B-methylbutyrate and where the composition is administered during at least a portion of the period of muscle disuse and at least a portion of the muscle recovery following the period of muscle disuse, and the period of muscle disuse and the period of muscle recovery are each at least 4 hours.
  • This embodiment also includes use of a composition comprising an effective amount of green tea extract and an effective amount of B-hydroxy-B-methylbutyrate for the manufacture of a medicament for preserving muscle strength of a subject during a period of muscle disuse and a period of muscle recovery following the period of muscle disuse wherein the composition is administered during at least a portion of the period of muscle disuse and at least a portion of the muscle recovery following the period of muscle disuse and the period of muscle disuse and the period of muscle recovery are each at least 4 hours.
  • methods of preserving muscle strength of a subject during a period of muscle disuse are disclosed.
  • the period of muscle disuse is at least about 4 hours.
  • the methods include administering a composition comprising an effective amount of leucine or a leucine metabolite and an effective amount of GTE to the subject during at least a portion of the period of muscle disuse.
  • This embodiment also includes a composition for use in preserving muscle strength of a subject during a period of muscle disuse, wherein the composition comprises an effective amount of green tea extract, and an effective amount of leucine or a leucine metabolite, and where the composition is administered during at least a portion of the period of muscle disuse, and the period of muscle disuse is at least 4 hours.
  • This embodiment also includes use of a composition comprising an effective amount of green tea extract and an effective amount of leucine or a leucine metabolite for the manufacture of a medicament for preserving muscle strength of a subject during a period of muscle disuse wherein the composition is administered during at least a portion of the period of muscle disuse and the period of muscle disuse is at least 4 hours.
  • methods of preserving muscle strength of a subject during a period of muscle disuse and a subsequent period of muscle recovery are disclosed.
  • the period of muscle disuse and the period of muscle recovery are each at least about 4 hours.
  • the methods include administering a composition comprising an effective amount of leucine or a leucine metabolite and an effective amount of GTE to the subject during at least a portion of both the period of muscle disuse and the period of muscle recovery.
  • This embodiment also includes a composition for use in preserving muscle strength of a subject during a period of muscle disuse and a period of muscle recovery following the period of muscle disuse, wherein the composition comprises an effective amount of green tea extract, and an effective amount of leucine or a leucine metabolite, and where the composition is administered during at least a portion of the period of muscle disuse and at least a portion of the muscle recovery following the period of muscle disuse, and the period of muscle disuse and the period of muscle recovery are each at least 4 hours.
  • This embodiment also includes use of a composition comprising an effective amount of green tea extract and an effective amount of leucine or a leucine metabolite for the manufacture of a medicament for preserving muscle strength of a subject during a period of muscle disuse and a period of muscle recovery following the period of muscle disuse wherein the composition is administered during at least a portion of the period of muscle disuse and at least a portion of muscle recovery following the period of muscle disuse and the period of muscle disuse and the period of muscle recovery are each at least 4 hours.
  • FIGURE 1 illustrates muscle strength performance of non-immobilized limbs of rats after the rats consumed compositions comprising HMB, GTE, neither, or both.
  • FIGURE 2 illustrates muscle strength performance of immobilized limbs of rats after the rats consumed compositions comprising HMB, GTE, neither, or both.
  • Methods of preserving muscle strength of a subject during a period of muscle disuse are disclosed herein.
  • Muscle strength is preserved by administering a composition comprising an effective amount of HMB and GTE to the subject.
  • the methods comprise administering at least one serving per day of a composition comprising from about 0.1 to about 10 g HMB and from about 20 mg to about 2,000 mg GTE per serving to the subject. It has been unexpectedly found that administering compositions containing HMB and GTE is more effective at preserving muscle strength than administering compositions containing either ingredient alone.
  • methods of preserving muscle strength of a subject during a period of muscle disuse are disclosed.
  • the period of muscle disuse is at least 4 hours.
  • the period of muscle disuse is from about 24 hours to about 36 months.
  • the methods include administering a composition comprising an effective amount of HMB and an effective amount of GTE to the subject during at least a portion of the period of muscle disuse.
  • methods of preserving muscle strength of a subject during a period of muscle disuse and a subsequent period of muscle recovery are also disclosed.
  • Muscle strength is preserved by administering a composition comprising an effective amount of HMB and an effective amount of GTE to the subject during at least a portion of both the period of muscle disuse and the period of muscle recovery.
  • the period of muscle disuse and the period of muscle recovery are each at least about 4 hours.
  • Methods of preserving muscle strength of a subject during a period of muscle disuse are also disclosed. Muscle strength is preserved by administering a composition comprising an effective amount of leucine or a leucine metabolite (other than HMB) and an effective amount of GTE to the subject.
  • exemplary leucine metabolites include but are not limited to a-ketoisocaproic acid, a-hydroxyisocaproic acid, or a combination thereof.
  • methods of preserving muscle strength of a subject during a period of muscle disuse are disclosed.
  • the period of muscle disuse is at least 4 hours.
  • the methods include administering a composition comprising an effective amount of leucine or a leucine metabolite and an effective amount of GTE to the subject during at least a portion of the period of muscle disuse.
  • methods of preserving muscle strength of a subject during a period of muscle disuse and a subsequent period of muscle recovery are disclosed.
  • the period of muscle disuse and the period of muscle recovery are each at least 4 hours.
  • the methods include administering a composition comprising an effective amount of leucine or a leucine metabolite and an effective amount of GTE to the subject during at least a portion of both the period of muscle disuse and the period of muscle recovery.
  • administering or “being administered” as used herein, unless otherwise specified, should be understood to comprise at least one of: a) providing the composition to a subject; and b) the act of consuming the composition. Unless otherwise indicated, the composition is administered to the subject orally or enterally.
  • muscle disuse refers to a substantial lack of activity of a particular muscle, muscle type, or muscle group due to partial or full immobilization, casting, injury, illness, bed rest, hospitalization, extended air travel (e.g., flights that are at least 4 hours in duration), weightlessness, and the like.
  • muscle recovery refers to use of a particular muscle, muscle type, or muscle group, after a period of muscle disuse. Muscle recovery may include gentle stretching, contraction, and movement of the muscles (e.g., walking around the house) and structured rehabilitation after the muscles have been inactive. Muscle recovery may, but does not necessarily, include strenuous exercise, including weight- bearing, resistance, and cardiovascular exercise, to quickly rebuild and increase muscle mass and muscle strength.
  • the nutritional compositions comprise at least one of a source of protein, a source of carbohydrate, and a source of fat.
  • liquid nutritional composition as used herein, unless otherwise specified, are used interchangeably to refer to nutritional compositions in ready- to-drink liquid form, e.g., liquid nutritional products; concentrated liquid form; and nutritional liquids made by reconstituting nutritional powders as described herein prior to use.
  • the liquid nutritional composition may be formulated as a suspension, an emulsion, a solution, and the like.
  • nutritional powder or “powdered nutritional composition” as used herein, unless otherwise specified, are used interchangeably to refer to nutritional compositions in a solid flowable or scoopable form, and includes spray-dried powders, extruded, dry-mixed, or dry-blended powders, and the like.
  • a nutritional powder may be reconstituted upon addition of water or another liquid to form a liquid nutritional composition prior to being administered to a subject.
  • period refers to a continuous interval of time.
  • a period may be about 4 hours, about 8 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about one week, about two weeks, about one month, about two months, about three months, about six months, about nine months, about twelve months, or longer than twelve months in duration.
  • period of muscle disuse refers to the interval of time that the muscle or muscles are substantially inactive.
  • a period of muscle disuse is at least 4 hours of substantially continuous muscle inactivity.
  • occasional short intervals of mild muscle use such as sitting up in bed or moving from bed to toilet, may be included within a period of muscle disuse.
  • period of muscle recovery refers to the interval of time that the muscle or muscles are active, for the purpose of regaining at least some muscle mass and strength after a period of muscle disuse.
  • the period of muscle recovery will typically closely follow in time a period of muscle disuse.
  • a period of muscle recovery is at least 4 hours of intermittent sessions of deliberate muscle activity, which may include intervals of rest and sleep between the sessions of muscle activity.
  • a "24 hour period of muscle recovery” does not necessarily refer to 24 hours of continuous muscle activity without rest.
  • serving refers to an amount of nutritional composition that is intended for consumption or otherwise consumed in one sitting, which may last up to one or up to two hours.
  • solid nutritional composition refers to nutritional products that are in solid form.
  • Some examples of solid nutritional products include: bars; sticks; cookies, breads, cakes, or other baked good; frozen liquids; candy; breakfast cereals; snack chips or bites; frozen or retorted entrees; and the like.
  • subject refers to an animal, including but not limited to, a human, a domesticated farm animal (e.g., cow, horse, pig, or chicken), or a pet (e.g., dog or cat). In certain embodiments, the subject is a human.
  • a domesticated farm animal e.g., cow, horse, pig, or chicken
  • a pet e.g., dog or cat
  • the subject is a human.
  • compositions of the present disclosure comprise HMB.
  • Any source of HMB is suitable for use herein. Suitable sources of HMB include HMB as a free acid, a salt, an anhydrous salt, an ester, a lactone, or other product forms that otherwise provide a bioavailable form of HMB in the composition.
  • suitable salts of HMB for use herein include sodium, potassium, calcium, magnesium, chromium, or other non-toxic HMB salts.
  • Suitable HMB salts may be in anhydrous or hydrated forms.
  • Calcium HMB monohydrate is a preferred source of HMB, and is commercially available from, for example, Technical Sourcing International (TSI), Missoula, Montana.
  • the effective concentration of HMB in the liquid may be up to about 10%, including from about 0.01% to about 10%>, including from about 0.1%o to about 10%), including from about 0.1 % to about 5%, including from about 0.1 % to about 3%o, including from about 0.1 % to about 2%, including from about 0.1% to about 1.5%, including from about 0.1 % to about 1%, including from about 0.3% to about 10%, including from about 0.5% to about 10%, including from about 0.7% to about 10%, including from about P/o to about 10%), including from about 2% to about 10%, including from about 3% to about 10%), and including from about 5% to about 10% by weight of the liquid.
  • the effective concentration of HMB in the solid may be up to about 10%, including from about 0.1% to about 10%, including from about 0.1% to about 7%o, including from about 0.1% to about 5%, including from about 0.1% to about 3%, including from about 0.1% to about 2%, including from about 0.1% to about 1.5%, including from about 0.1% to about 1.0%, including from about 0.3% to about 10%, including from about 0.5%) to about 10%), including from about 1% to about 10%, including from about 2% to about 10%, including from about 3% to about 10%, including from about 4% to about 10%>, including from about 5% to about 10%>, and including from about 7% to about 10%> by weight of the solid.
  • compositions may provide from about 0.1 g/day to about 10 g/day of HMB in accordance with the methods described herein, including from about 0.1 g/day to about 5 g/day, including from about 0.1 g/day to about 3 g/day, including from about 0.1 g/day to about 2 g/day, including from about 0.1 g/day to about 1.5 g/day, including from about 0.1 g/day to about 1 g/day, including from about 0.3 g/day to about 10 g/day, including from about 0.3 g/day to about 5 g/day, including from about 0.3 g/day to about 3 g/day, including from about 0.3 g/day to about 1 g/day, including from about 0.5 to about 10 g/day, including from about 0.5 g/day to about 5 g/day, including from about 0.5 g/day to about 3 g/day, including from about 0.75 g/day to about 10 g/day, including
  • compositions of the present disclosure may comprise leucine or other metabolites of leucine instead of HMB.
  • compositions comprising leucine or other metabolites of leucine and GTE may enhance the preservation of muscle strength in subjects during periods of muscle disuse.
  • HICA a-hydroxyisocaproic acid
  • leucic acid 2- hydroxy-4-methylvaleric acid
  • 2- hydroxy-4-methylvaleric acid is an end product of leucine metabolism in human tissues.
  • HICA a particularly useful form of HICA for use in the methods and compositions disclosed herein is the calcium salt of HICA, which may include the anhydrous monohydrate thereof.
  • the HICA used in the compositions of the present disclosure can come from any source, and, in certain embodiments, the HICA is L-2-hydroxy-4-methylvaleric acid.
  • HICA is commercially available from, for example, Ark Pharm Inc., Libertyville, Illinois or TCI America, Portland, Oregon.
  • the amount of HICA in the compositions is from about
  • the amount of HICA is from about 0.5 g/serving to about 2 g/serving, including from about 1 g/serving to 1.5 g/serving.
  • the amount of HICA administered per day includes from about 0.15 g/day to about 10 g/day of HICA, including from about 0.5 g/day to about 7 g/day, including from about 1 g/day to about 5 g/day of HICA.
  • a subject may be administered one serving per day, two servings per day, three servings per day, or four or more servings per day to receive the desired amount of HICA.
  • KIC a-ketoisocaproic acid
  • ketoleucine also known as ketoleucine or 4-methyl-2-oxopentanoic acid
  • KIC is an intermediate product of leucine metabolism in human tissues.
  • One particularly useful form of KIC for use in the methods and compositions disclosed herein is the calcium salt of KIC, which may include the anhydrous monohydrate thereof.
  • the KIC used in the compositions of the present disclosure can come from any source, and is commercially available from, for example, TCI America, Portland, Oregon or Finetech Industry Ltd, London, UK.
  • the amount of KIC in the compositions is from about
  • the amount of KIC is from about 0.3 g/serving to 3 g/serving, including from about 0.5 g/serving to 1.5 g/serving.
  • the amount of KIC administered per day includes from about 0.15 g/day to 10 g/day of KIC, including from about 0.3 g/day to about 7 g/day, including from about 0.5 g/day to 5 g/day of KIC.
  • a subject may be administered one serving per day, two servings per day, three servings per day, or four or more servings per day to receive the desired amount of KIC.
  • compositions of the present disclosure comprise GTE.
  • GTE disclosed herein is derived from green tea leaves.
  • GTE comprises a polyphenol, epigallocatechin gallate ("EGCg"), either alone or in combination with other polyphenol compounds, which is isolated from green tea as an extract.
  • the GTE may be in the form of a liquid, a solid (e.g., a powder), and mixtures thereof.
  • GTE is commercially available from, for example, Taiyo International, Inc., Minneapolis, Minnesota.
  • suitable green tea extracts used with the compositions disclosed herein may contain other polyphenols including but not limited to, other catechins such as catechin (i.e., (+)-catechin, also known as “C”), epicatechin (“EC”), gallocatechin (“GC”), epigallocatechin (“EGC”), and epicatechin gallate (“ECg”); flavones such as apigenin, isoviloxin, sapotarin, and vicenin-2; flavonols such as kaempherol, quercetin, and myricetin; condensed flavonoids; and tannin glycosides.
  • catechin i.e., (+)-catechin, also known as "C”
  • C epicatechin
  • GC gallocatechin
  • ECC epigallocatechin
  • ECg epicatechin gallate
  • flavones such as apigenin, isoviloxin, sapotarin, and vicenin-2
  • flavonols such as kaempherol,
  • the green tea extracts disclosed herein include at least one of C, EC, GC, EGC, ECg, and combinations thereof.
  • the GTE may contain caffeine, contain a trace amount of caffeine, or may be substantially free of caffeine (i.e., decaffeinated).
  • the green tea extract contains about 20% by solid weight of EGCg, including about 25%, about 30%>, about 40%>, about 50%>, about 70%>, about 80%), about 90%>, and about 100% by solid weight of EGCg.
  • the green tea extract contains from about 20% to 100% by solid weight of EGCg, including from about 25% to 100%, about 30% to 100%, about 40% to 100%, about 50% to 100%, about 70% to 100%, about 80% to 100%, and about 90% to 100% by solid weight of EGCg.
  • the green tea extract may contain about 0%> to about 20%> by solid weight of EC, including from about 4% to about 15%, and from about 5% to about 10% by solid weight of EC.
  • the EC content of the compositions disclosed herein may be fortified or supplemented by including sources of EC other than green tea extract, such as cocoa.
  • compositions of the present disclosure may provide from about 20 mg/day to about 2,000 mg/day of GTE in accordance with the methods described herein. Accordingly, the compositions may include about 40 mg/day to about 2,000 mg/day of GTE, including from about 100 mg/day to about 2,000 mg/day, from about 250 mg/day to about 2,000 mg/day, from about 500 mg/day to about 2,000 mg/day, from about 750 mg/day to about 2,000 mg/day, from about 20 mg/day to about 1,500 mg/day, from about 20 mg/day to about 1,000 mg/day, from about 20 mg/day to about 750 mg/day, from about 20 mg/day to about 500 mg/day, from about 20 mg/day to about 250 mg/day, and from about 20 mg/day to about 100 mg/day of GTE.
  • compositions of the present disclosure comprise
  • HMB and GTE in a weight ratio HMB:GTE
  • the weight ratio of HMB: GTE in the composition is from about 1 :1 to about 7: 1, including from about 1.5 : 1 to about 6:1, and including from about 2: 1 to about 5: 1.
  • the HMB and GTE are formulated into a suitable composition and then, in accordance with the methods disclosed herein, administered to a subject in a form adapted to the chosen route of administration.
  • the compositions disclosed herein include, but are not limited to, those suitable for oral administration.
  • Oral administration refers to any form of administration in which the composition including HMB and GTE passes through the esophagus of the subject.
  • oral administration typically refers to oral consumption, but may also include other forms of enteral administration (i.e., administration through the digestive track).
  • Other forms of enteral administration suitable for use with the methods disclosed herein include nasogastric, gastric, or jejunal intubation.
  • the compositions including the HMB and GTE disclosed herein are formulated as medicaments.
  • suitable forms of the composition as a medicament include caplets, tablets, pills, capsules, chewable tablets, quick dissolve tablets, effervescent tablets, solutions, suspensions, emulsions, multi-layer tablets, bi- layer tablets, soft gelatin capsules, hard gelatin capsules, lozenges, chewable lozenges, beads, granules, particles, microparticles, sachets, and combinations thereof.
  • the composition may be in the form of a powder or liquid concentrate packaged in a sachet, the contents of which may be added to water or other potable liquid to form a beverage.
  • compositions containing the HMB and GTE are formulated as nutritional compositions.
  • Such nutritional compositions disclosed herein are useful in providing supplemental, primary, or sole sources of nutrition, including providing the subjects one or more benefits as described herein.
  • Suitable nutritional compositions for oral administration include solid, liquid, semi-solid, and semi-liquid nutritional products.
  • Non-limiting examples of solid nutritional product forms suitable for use in the methods herein include snack and meal replacement products, including: bars; sticks; cookies, breads, cakes, or other baked goods; frozen liquids; candy; breakfast cereals; powders, granulated solids, or other particulates; molded or compressed powders; snack chips or bites; frozen or retorted entrees; and so forth.
  • Nonlimiting examples of liquid nutritional product forms suitable for use herein include snack and meal replacement products, hot or cold beverages, carbonated or non- carbonated beverages, juices or other acidified beverages, milk or soy-based beverages, shakes, coffees, teas, low-volume liquid “shooters,” enteral feeding compositions, and so forth.
  • These liquid compositions are most typically formulated as suspensions or emulsions, but can also be formulated in any other suitable forms such as clear liquids, substantially clear liquids, solutions, and so forth.
  • the nutritional products may be in the form of semi-solids, which include those forms that are intermediate in properties, such as rigidity, between solids and liquids.
  • semi-solids include puddings, gelatins, and doughs.
  • the nutritional products may be in the form of semi-liquids, which include those forms that are intermediate in properties, such as flow properties, between liquids and solids.
  • exemplary semi-liquids include thick shakes and liquid gels.
  • the quantity of nutritional composition that provides effective amounts of HMB and GTE to the subject may be administered as a single serving or as multiple servings per day.
  • the nutritional composition provides up to 500 kilocalories (kcal) of energy per serving or dose, including from 20 kcal to 500 kcal, from 75 kcal to 500 kcal, from 150 kcal to 500 kcal, from 250 kcal to 500 kcal, from 300 kcal to 500 kcal, or from 400 kcal to 500 kcal per serving.
  • kcal kilocalories
  • the compositions disclosed herein may be nutritional compositions which include at least one of a source of protein, a source of carbohydrate, and a source of fat.
  • the amount or concentration of the at least one source of protein, source of carbohydrate, and source of fat present in the nutritional compositions may vary widely depending on the product formulation of the nutritional composition (e.g., clear liquid, fat-based emulsion).
  • the amount or concentration of the at least one source of protein, source of carbohydrate, and source of fat may be characterized based upon a percentage of the total calories per serving in the nutritional composition.
  • the amount or concentration of the at least one source of protein, source of carbohydrate, and source of fat present in the nutritional composition can be within the ranges described in Samples A-E, as shown in Table 1 below.
  • the source of protein is present in the nutritional composition in an amount sufficient to provide 5 g/serving to 50 g/serving of protein, including from 6 g/serving to 45 g/serving and from 10 g/serving to 30 g/serving of protein.
  • any source of protein may be used so long as it is suitable for nutritional compositions and is otherwise compatible with any other selected ingredients or features in the nutritional composition.
  • the at least one source of protein may include, but is not limited to, intact, hydrolyzed, and partially hydrolyzed protein, which may be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy, potato, pea), and combinations thereof.
  • the at least one source of protein may also include a mixture amino acids (often described as free amino acids) known for use in nutritional products or a combination of such amino acids with the intact, hydrolyzed, and partially hydrolyzed proteins described herein.
  • the amino acids may be naturally occurring or synthetic amino acids.
  • suitable sources of protein for use in the nutritional compositions disclosed herein include, but are not limited to, whey protein concentrates, whey protein isolates, whey protein hydrolysates, acid caseins, sodium casemates, calcium casemates, potassium casemates, casein hydrolysates, milk protein concentrates, milk protein isolates, milk protein hydrolysates, nonfat dry milk, condensed skim milk, soy protein concentrates, soy protein isolates, soy protein hydrolysates, pea protein concentrates, pea protein isolates, pea protein hydrolysates, collagen proteins, potato proteins, rice proteins, insect proteins, earthworm proteins, fungal (e.g., mushroom) proteins, proteins expressed by microorganisms (e.g., bacteria and algae), and the like, as well as combinations thereof.
  • the nutritional compositions can include any individual source of protein or a combination of two or more of the various sources of protein listed above or otherwise encompassed by the general inventive concepts.
  • the source of carbohydrate is present in an amount sufficient to provide the nutritional composition 15 g/serving to 1 10 g/serving of carbohydrate, including from 25 g/serving to 90 g/serving and from 40 g/serving to 65 g/serving of carbohydrate.
  • Carbohydrates suitable for use in the nutritional compositions disclosed herein may be simple, complex, variations, or combinations thereof. Any source of carbohydrate may be used so long as it is suitable for use in nutritional compositions and is otherwise compatible with any other selected ingredients or features present in the nutritional composition.
  • Non- limiting examples of a source of carbohydrate suitable for use in the nutritional compositions disclosed herein include: maltodextrin; hydro lyzed or modified starch or cornstarch; glucose polymers; corn syrup; corn syrup solids; rice-derived carbohydrates; high fructose corn syrup; honey; sugar alcohols, such as maltitol, erythritol, sorbitol, glycerin, and the like; sucrose; glucose; fructose; lactose; isomaltulose, sucromalt, pullulan, potato starch, and other slowly- digested carbohydrates; oligosaccharides such as fructo-oligosaccharides; dietary fibers including, but not limited to, oat fiber, soy fiber, gum arabic, sodium carboxymethylcellulose, methylcellulose, guar gum, gellan gum, locust bean gum, konjac flour, hydroxypropyl methylcellulose, tragacanth gum, karaya gum, gum acacia,
  • the nutritional compositions can include any individual source of carbohydrate or a combination of two or more of the various sources of carbohydrate listed above or otherwise encompassed by the general inventive concepts.
  • the composition is a nutritional composition and contains a source of fat
  • the source of fat is present in an amount sufficient to provide the nutritional composition about 0.1 g/serving to about 45 g/serving of fat, including from about 5 g/serving to about 35 g/serving and from about 10 g/serving to about 30 g/serving of fat.
  • the nutritional composition containing at least one source of fat, the nutritional composition is in the form of a liquid emulsion.
  • Any source of fat may be used so long as it is suitable for use in nutritional compositions and is otherwise compatible with any other selected ingredients or features present in the nutritional composition.
  • the source of fat may be derived from plants, animals, and combinations thereof.
  • suitable sources of fat for use in the nutritional compositions described herein include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic acid safflower oil, medium chain triglyceride oil, high gamma linolenic acid (GLA) safflower oil, sunflower oil, high oleic acid sunflower oil, palm oil, palm kernel oil, palm olein, canola oil, marine oils, fish oils, algal oils, transgenic oils, cottonseed oils, interesterified oils, transesterified oils, eicosapentaenoic acid, docosahexaenoic acid, and the like, as well as combinations thereof.
  • the nutritional compositions can include any individual source of fat or
  • the nutritional powders described herein may further comprise other optional ingredients that may modify the physical, chemical, hedonic, or processing characteristics of the products or serve as additional nutritional components when used for a targeted population.
  • optional ingredients are known or otherwise suitable for use in other nutritional products and may also be used in the nutritional powders described herein, provided that such optional ingredients are safe and effective for oral administration and are compatible with the essential and other ingredients in the selected product form.
  • the nutritional compositions may include other compounds or sources of such compounds that are anabolic for muscle, stimulate muscle protein synthesis, decrease muscle protein degradation, or combinations thereof.
  • examples of such compounds include, but are not limited to, leucine, isoleucine, valine, glycine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan, carnitine, carnosine, creatine, taurine, arginine, anserine, mushroom extract, cordycepic acid, spinach extract, arugula extract, broccoli extract, eggplant skin extract, plum extract, apple extract, ursolic acid, grape extract, resveratrol, bioidentical stilbenes such as pTeroPureTM, olive extract, and metabolites of any of the foregoing.
  • the nutritional compositions include at least one source of a compound selected from the group consisting of leucine, isoleucine, valine, glycine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan, carnitine, carnosine, creatine, and metabolites of any of the foregoing, as well as combinations thereof.
  • the compositions may include a high intensity sweetener to counter, mask, or otherwise obscure the potent taste of the green tea extract, particularly the EGCg present in the green tea extract, which may be described as sour, astringent, and bitter, as well as to counter, mask, or otherwise obscure the taste of any of the other polyphenols in the green tea extract that may be present in the composition.
  • a high intensity sweetener to counter, mask, or otherwise obscure the potent taste of the green tea extract, particularly the EGCg present in the green tea extract, which may be described as sour, astringent, and bitter, as well as to counter, mask, or otherwise obscure the taste of any of the other polyphenols in the green tea extract that may be present in the composition.
  • high intensity sweeteners examples include, but are not limited to, sucralose, acesulfame potassium (also known as “acesulfame K” or “ace K"), aspartame, stevia, neotame, neohesperidine DC, alitame, monellin, thaumatin, mogrosides, monk fruit, and the like. Combinations of the high intensity sweeteners listed above may be used.
  • the amount of the high intensity sweetener in the composition may vary depending upon the particular high intensity sweetener selected, other ingredients in the formulation, and other formulation or product target variables. Different high intensity sweeteners themselves have different sweetness intensities (e.g.
  • acesulfame K is approximately 200 times sweeter than sucrose, as compared to sucralose which is approximately 600 times sweeter than sucrose), and therefore may require more or less sweetener relative to other sweeteners.
  • certain carbohydrates which may already be present in the compositions disclosed herein, are sweeteners that may at least partially counter or at least partially mask the taste of the green tea extract in such compositions.
  • the liquid compositions disclosed herein may comprise a viscosity agent, e.g., thickening agent.
  • a viscosity agent e.g., thickening agent.
  • the viscosity agent is used in the thicker types of liquid compositions, for example, fat-based emulsions, shakes, etc.
  • Any viscosity agent that is known or otherwise suitable for use in a composition is also suitable for use herein, some non- limiting examples of which include starches, such as modified corn starch, wheat starch (including pregelatinized wheat starch), potato starch, rice starch, tapioca starch, and the like; blends of cellulose gel and cellulose gum; blends of micro crystalline cellulose and sodium carboxymethyl cellulose; pectin; carrageenan; agar; gellan gum; alginates; gum acacia; gelatin; methyl cellulose; hydroxypropylcellulose; and combinations thereof.
  • starches such as modified corn starch, wheat starch (including pregelatinized wheat starch), potato starch, rice starch, tapioca starch, and the like
  • blends of cellulose gel and cellulose gum blends of micro crystalline cellulose and sodium carboxymethyl cellulose
  • pectin carrageenan
  • agar gellan gum
  • alginates alginates
  • gum acacia ge
  • the viscosity agent is present in an amount of 0% to about 5.0%, including from about 0.1% to about 3%), including from about 0.5%> to about 1.5%, by solid weight based on the total weight of the composition.
  • the powder compositions disclosed herein include at least one wetting agent.
  • wetting agents act to improve and hasten the interaction between the powder composition and the impinging liquid (e.g., water). The wetting agent thus assists in more quickly reconstituting the powder composition into a suitable liquid composition.
  • Suitable wetting agents include phospholipids, mono- and diglycerides, mono- and diglyceride oil, diacetyl tartaric acid ester of mono- and diglycerides (DATEM), and other emulsifiers and surfactants.
  • DATEM diacetyl tartaric acid ester of mono- and diglycerides
  • the powder compositions disclosed herein include at least one anti-caking agent.
  • these agents help to maintain the powder particles as loose, free-flowing particles with a reduced tendency to form large clumps as the powder sits over time.
  • Silicon dioxide is an example of one suitable anti-caking agent.
  • compositions disclosed herein may comprise one or more compounds selected from beta-alanine, human milk oligosaccharides, prebiotics, probiotics, nucleotides, nucleosides, carotenoids (e.g., lutein, beta-carotene, lycopene, and zeaxanthin), and combinations thereof.
  • compositions disclosed herein may also contain other ingredients, non-limiting examples of which include, preservatives, antioxidants in addition to those found in the GTE, buffers, pharmaceutical actives, additional nutrients, colorants, flavors, emulsifiers, anti-foaming agents, and the like.
  • the compositions may also contain vitamins or related nutrients including, but not limited to, curcumin, fish oil, vitamin A, vitamin D (cholecalciferol, 25 -hydro xycholecalciferol, 1 ,25 -dihydroxy cholecalciferol, 24,25-dihydroxycholecalciferol, ergocalciferol), vitamin E, vitamin Kl , vitamin K2, thiamine, riboflavin, pyridoxine, vitamin B12, niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts, derivatives thereof, and combinations thereof.
  • vitamins or related nutrients including, but not limited to, curcumin, fish oil, vitamin A, vitamin D (cholecalciferol, 25 -hydro xycholecalciferol, 1 ,25 -dihydroxy cholecalciferol, 24,25-dihydroxycholecalciferol, ergocalciferol), vitamin
  • compositions disclosed herein may also contain minerals including, but not limited to, calcium, phosphorus, magnesium, iron, manganese, copper, sodium, potassium, molybdenum, chromium, selenium, chloride, zinc, and combinations thereof.
  • Table 2 shows an exemplary formulation of an emulsion-type liquid nutritional composition containing protein, carbohydrate, fat, HMB and GTE. Assuming a density of 1.075 g/mL and a serving size of about 237 mL (about 8 fl. oz.), a nutritional composition made according to the formulation shown in Table 2 has about 1.5 g calcium HMB monohydrate and about 500 mg of GTE per serving.
  • y roc o e y oxne y roc or e, o avn, o c c , otn, yanoco aamn, etc.
  • Table 3 shows an exemplary formulation of a clear-type liquid nutritional composition that is substantially free of fat and contains protein, carbohydrate, HMB and GTE. Assuming a density of 1.05 g/mL and a serving size of about 237 mL (about 8 fl. oz.), a nutritional composition made according to the formulation shown in Table 3 has about 1.5 g calcium HMB monohydrate and about 500 mg of GTE per serving.
  • compositions disclosed herein may be prepared by any process or suitable method (now known or known in the future) for making the selected product form, such as a powder, solid, semi-solid, liquid, or semi-liquid nutritional composition.
  • suitable method now known or known in the future
  • the manufacturing processes for the compositions of the present disclosure may be carried out in ways other than those set forth herein without departing from the spirit and scope of the present disclosure.
  • the present embodiments are, therefore, to be considered in all respects illustrative and not restrictive, and all changes and equivalents also come within the description of the present disclosure.
  • a protein-in-fat (PIF) slurry a protein-in-fat (PIF) slurry, a carbohydrate-mineral (CHO-MIN) slurry, and a protein-in-water (PIW) slurry.
  • PIF protein-in-fat
  • CHO-MIN carbohydrate-mineral
  • PIW protein-in-water
  • the PIF slurry is formed by heating and mixing an oil (e.g. , soy oil, canola oil or corn oil) and then adding an emulsifier (e.g., lecithin), fat soluble vitamins, and a portion of the total protein (e.g., milk protein concentrate) with continued heat and agitation.
  • an oil e.g. , soy oil, canola oil or corn oil
  • an emulsifier e.g., lecithin
  • fat soluble vitamins e.g., lecithin
  • a portion of the total protein e.g., milk protein concentrate
  • the CHO-MIN slurry is formed by adding with heated agitation to water: minerals (e.g., potassium citrate, dipotassium phosphate, or sodium citrate), including trace and ultra trace minerals (e.g., Ultra Trace Mineral/Trace Mineral Premix), thickening or viscosity agents (e.g., cellulose gel, gellan, or carrageenan), and HMB, typically as calcium HMB.
  • minerals e.g., potassium citrate, dipotassium phosphate, or sodium citrate
  • trace and ultra trace minerals e.g., Ultra Trace Mineral/Trace Mineral Premix
  • thickening or viscosity agents e.g., cellulose gel, gellan, or carrageenan
  • HMB typically as calcium HMB.
  • the resulting CHO-MIN slurry is held for 10 minutes with continued heat and agitation before adding additional minerals (e.g., potassium chloride, magnesium carbonate, or potassium iodide) and the carbohydrates (e.g., sucrose or
  • the three slurries are blended together with heat and agitation and the pH is adjusted to the desired range, e.g., from 6.6 to 7, after which the composition is subjected to high-temperature short-time (“HTST") processing.
  • the composition is heat treated, emulsified, homogenized, and cooled during HTST.
  • Water soluble vitamins and ascorbic acid are added (if applicable), the pH is again adjusted (if necessary), flavors are added, and any additional water can be added to adjust the solids content to the desired range.
  • the green tea extract is prepared as a solution (e.g., 1% w/w) by adding GTE to water and agitating for 0-24 hours.
  • the solution of green tea extract is added to the composition containing the other ingredients and is agitated for a period of time (e.g., 5 to 60 minutes) to ensure homogeneous distribution of the green tea extract in the composition.
  • the agitation associated with the preparation of the solution containing the green tea extract, as well as the agitation associated with the addition of such green tea extract solution to the other ingredients, may take place at 4° C to 50° C.
  • the liquid nutritional composition may optionally be sterilized according to any suitable sterilization technique (e.g., aseptic, retort, hot-fill, chemical, radiation, and filtering sterilization techniques) and packaged.
  • a liquid nutritional composition is dried to form a nutritional powder using any methods known in the art.
  • nutritional powders can be manufactured by preparing one or more slurries, as described above, which are then mixed, heat treated, standardized, heat treated a second time, evaporated to remove water, and spray dried or dry blended to form a reconstitutable nutritional powder.
  • the spray drying may include any spray drying technique that is suitable for use in the production of nutritional powders. Many different spray drying methods and techniques are known for use in the nutrition field, all of which are suitable for use in the manufacture of the spray dried nutritional powders herein. Following drying, the finished powder may be packaged into any suitable container (e.g., a metal canister or plastic jar).
  • the method for preparing the nutritional powder comprises preparing an extruded powder.
  • the dry ingredients of the nutritional powder are incorporated in the extruder hopper in the form of a dry feed or powder premix.
  • the dry nutritional ingredients enter the extruder just after the point of entry of water.
  • the water comprises from about 1% to about 80% by weight of the total weight of the water and dry ingredients. The amount of water added to the nutritional composition may be adjusted within the aforementioned ranges based on the desired physical properties of the extrudate.
  • the nutritional ingredients may be premixed with water to form a thick emulsion, which is then fed into the extruder hopper in the form of a viscous liquid or sludge.
  • extrudate refers to all or a portion of a nutritional composition that exits an extruder.
  • the extruder used to produce the nutritional powder or extrudate operates in a continuous format.
  • any extruder known for use in food processing may be utilized.
  • extrusion is performed via a screw extruder.
  • Said screw extruder may be a twin screw extruder or a single screw extruder.
  • the extruder screws may consist of shear elements, mixing elements, conveying elements, kneading elements, emulsifying elements, disc elements, or a combination of the above in any interchangeable order.
  • the barrels of the extruder may be steam heated or electrically heated.
  • extrusion takes place at a temperature between about 20 °C to about 99 °C, from about 30 °C to about 150 °C, or from about 70 °C to about 100 °C.
  • the ingredients are processed in the extruder for about 5 seconds to about 240 seconds or for about 30 seconds to about 180 seconds.
  • the extrudate is dried following extrusion so as to remove most or all of the water contained therein.
  • any conventional drying methods may be used to remove the desired amount of water from the nutritional powder.
  • the nutritional powder extrudate may be dried using a vacuum, convective hot air, a tray dryer, infrared, or any combination of the above.
  • the nutritional powder extrudate may be further ground or milled to a desired particle size following drying.
  • additional protein and carbohydrate ingredients may be added to the final nutritional powder in the form of dry ingredients or a dry blend.
  • compositions containing HMB and GTE are administered orally in accordance with the present disclosure to a subject as needed to preserve muscle strength during a period of muscle disuse or muscle recovery.
  • the period of muscle disuse may be due to any number of reasons, including for example partial or full immobilization, casting, injury, illness, bed rest, hospitalization, extended air travel, weightlessness, and the like, as noted above.
  • the compositions containing HMB and GTE may be administered to a subject solely during the period of muscle disuse or solely during the period of muscle recovery. However, to preserve muscle strength more fully, it is generally desirable to administer the composition containing HMB and GTE to the subject during at least a portion of both the period of muscle disuse and the period of muscle recovery.
  • the composition containing HMB and GTE is administered to the subject for the entire, or substantially entire, period of muscle disuse and the entire, or substantially entire, period of muscle recovery.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse resulting from a portion of the subject's body being immobilized in a cast.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse as a result of a severe illness such as cancer.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse that occurs while recovering from surgery.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to muscle disuse that occurs during hospitalization.
  • the subject may be a child, a pregnant woman, or an adult who is susceptible to loss of muscle strength due to muscle disuse that occurs during prolonged bed rest.
  • the subject may be a child or an adult who is susceptible to loss of muscle strength due to extended air travel, i.e., flights that are at least 4 hours in duration.
  • the subject may be an adult who is susceptible to loss of muscle strength due to muscle disuse resulting from time spent in low-gravity conditions.
  • the subject may be an adult or older adult who is susceptible loss of muscle strength due to muscle disuse resulting from prolonged inactivity.
  • the compositions including HMB and GTE can be administered to subjects during periods of muscle disuse.
  • the compositions disclosed herein are administered to the subject when the period of muscle disuse lasts at least 4 hours.
  • the compositions are administered to the subject when the period of muscle disuse lasts from about 4 hours to about 72 hours, including from about 4 hours to about 48 hours, including from about 4 hours to about 24 hours, including from about 4 hours to about 12 hours, including from about 8 hours to about 72 hours, including from about 8 hours to about 48 hours, including from about 8 hours to about 24 hours, including from about 12 hours to about 72 hours, including from about 12 hours to 48 hours, and including from about 12 hours to about 24 hours.
  • compositions are administered to the subject when the period of muscle disuse lasts from about 24 hours to about 36 months, including from about 24 hours to about 24 months, including from about 24 hours to about 12 months, including from about 24 hours to about 6 months, including from about 24 hours to about 3 months, including from about 24 hours to about 2 months, including from about 24 hours to about 1 month, including from about 24 hours to about 2 weeks, including from about 24 hours to about 1 week, including from about 48 hours to about 36 months, including from about 48 hours to about 24 months, including from about 48 hours to about 12 months, including from about 48 hours to about 6 months, including from about 48 hours to about 3 months, including from about 48 hours to about 2 months, including from about 48 hours to about 1 month, including from about 48 hours to about 2 weeks, including from about 48 hours to about 1 week, including from about 72 hours to about 12 months, including from about 72 hours to about 6 months, including about 72 hours to about 3 months, including from about 72 hours to about 1 month, including from about 72 hours to 2 weeks, including from about 72 hours to about 36 months, including
  • compositions disclosed herein can be administered to a subject for a period of muscle disuse lasting at least 4 hours, at least 8 hours, at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 1 week, at least 10 days, at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, at least 12 months, at least 24 months, at least 36 months, or for more than 36 months.
  • the compositions including HMB and GTE can be administered to subjects during periods of muscle disuse, as discussed above, and during subsequent periods of muscle recovery.
  • the compositions disclosed herein are administered to the subject when the period of muscle recovery lasts at least 4 hours.
  • the compositions are administered to the subject when the period of muscle recovery lasts from about 4 hours to about 72 hours, including from about 4 hours to about 48 hours, including from about 4 hours to about 24 hours, including from about 4 hours to about 12 hours, including from about 8 hours to about 72 hours, including from about 8 hours to about 48 hours, including from about 8 hours to about 24 hours, including from about 12 hours to about 72 hours, including from about 12 hours to 48 hours, and including from about 12 hours to about 24 hours.
  • compositions are administered to the subject when the period of muscle recovery lasts from about 24 hours to about 36 months, including from about 24 hours to about 24 months, including from about 24 hours to about 12 months, including from about 24 hours to about 6 months, including from about 24 hours to about 3 months, including from about 24 hours to about 2 months, including from about 24 hours to about 1 month, including from about 24 hours to about 2 weeks, including from about 24 hours to about 1 week, including from about 48 hours to about 36 months, including from about 48 hours to about 24 months, including from about 48 hours to about 12 months, including from about 48 hours to about 6 months, including from about 48 hours to about 3 months, including from about 48 hours to about 2 months, including from about 48 hours to about 1 month, including from about 48 hours to about 2 weeks, including from about 48 hours to about 1 week, including from about 72 hours to about 12 months, including from about 72 hours to about 6 months, including about 72 hours to about 3 months, including from about 72 hours to about 1 month, including from about 72 hours to 2 weeks, including from about 72 hours to about 36 months, including from
  • compositions disclosed herein can be administered to a subject for a period of muscle recovery lasting at least 4 hours, at least 8 hours, at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 1 week, at least 10 days, at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, at least 12 months, at least 24 months, at least 36 months, or for more than 36 months.
  • the number of days is intended to reflect the days in which the subject has been instructed to be administered the composition, and in which the composition is actually administered for at least 65%, including at least 70%, including at least 75%, including at least 80%, and including at least 90% of the instructed days during the period of administration.
  • compositions described herein may be provided to the subject in the form of servings.
  • the compositions may, but are not limited to, being administered as one serving per day, two servings per day, three servings per day, four servings per day, etc.
  • the compositions disclosed herein are administered in at least one serving per day or at least two servings per day.
  • the compositions disclosed herein are administered continuously or intermittently up to 24 hours per day by infusion through a nasogastric, gastric, or jejunal feeding tube.
  • the serving is within a range of from about 25 g to 500 g, including from about 50 g to about 400 g, including from about 75 g to about 300 g, including from about 100 g to about 250 g, and including from about 150 g to about 200 g.
  • the serving is within a range of about 5 mL to about 500 mL, including from about 25 mL to about 500 mL, including from about 50 mL to 450 mL, including from about 100 mL to 400 mL, including from about 150 mL to about 400 mL, including from about 175 mL to about 350 mL, including from about 200 mL to about 300 mL, and including from about 230 mL to about 250 mL.
  • the methods disclosed herein prevent the loss of skeletal muscle strength in a subject during a period of muscle disuse. In certain embodiments, the methods disclosed herein prevent the loss of skeletal muscle strength in a subject during a period of muscle disuse and during a subsequent period of muscle recovery.
  • SD rats were randomly assigned to one of 5 groups: one non-casted control group, one casted/recovery control group, and three casted/recovery test groups. Each group was fed ad libitum one of the following assigned diets, as provided in Table 4, for the duration of the test, beginning 7 days prior to initiation of casting and over the entire casting and recovery periods.
  • AIN-93M diets are well known balanced diets for rodents containing 12% protein.
  • the SD rats were assumed to have an approximate body weight of 500 g and an approximate food intake of 20 g/day.
  • the AIN-93M diet was supplemented with: a) HMB at a concentration of 8.5 gm/kg in the test diet, to deliver a dose of 340 mg/kg body weight of HMB per day to the Group 3 SD rats; b) GTE at a concentration of 1.25 gm/kg in the test diet, to deliver a dose of 50 mg/kg body weight of GTE per day to the Group 4 SD rats; or c) HMB at a concentration of 8.5 gm/kg plus GTE at a concentration of 1.25 g/kg in the test diet, to deliver a dose of 340 mg/kg body weight of HMB and 50 mg/kg body weight per day to the Group 5 SD rats.
  • Fig. 1 is a graph showing the force results for the non-immobilized limb of the SD rats taken at the end of the 7 day immobilization plus 7 day recovery period. No significant effect of dietary supplementation on muscle force production was observed in the plantaris muscle of the non-immobilized limb for any group.
  • Fig. 2 is a graph showing the force results for the immobilized limb of the SD rats taken at the end of the 7 day immobilization plus 7 day recovery period. In the immobilized limb, at lower test frequencies, the force produced by the plantaris muscle of the control non-casted group (Control, Group 1) was significantly less compared to all other groups of animals.
  • compositions of the present disclosure may include trace amounts of any optional or selected essential ingredient or feature described herein, provided that the remaining formulation still contains all of the required ingredients or features as described herein.
  • trace amount means that the selected formulation contains no more than 2 wt% of the optional ingredient, typically less than 1 wt%, and also includes zero percent, of such optional or selected essential ingredient, by weight of the compositions.
  • compositions of the present disclosure may also be substantially free of any optional ingredient or feature described herein, provided that the remaining formulation still contains all of the required ingredients or features as described herein.
  • substantially free means that the selected formulation contains less than a functional amount of the optional ingredient, typically less than about 1 wt%, including less than about 0.5 wt%, including less than about 0.1 wt%, and also including zero percent, of such optional ingredient, by weight of the compositions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention concerne des procédés de conservation de la force musculaire chez un sujet pendant une période d'inactivité musculaire. La présente invention concerne en outre des procédés de conservation de la force musculaire chez un sujet pendant une période d'inactivité musculaire et une période ultérieure de récupération musculaire. Les procédés comprennent l'administration d'une composition contenant du β-hydroxy-β-méthylbutyrate et un extrait de thé vert au sujet pendant au moins une partie de la période d'inactivité musculaire et, éventuellement, au cours d'au moins une partie de la période de récupération musculaire. La composition peut comprendre en outre la leucine ou un autre métabolite de la leucine, tel que l'acide alpha-céto-isocaproïque ou l'acide alpha-hydroxyisocaproïque.
PCT/US2015/050179 2014-09-16 2015-09-15 Procédés de conservation de la force musculaire au cours d'une période d'inactivité musculaire par administration de bêta-hydroxy-bêta-méthylbutyrate et d'un extrait de thé vert WO2016044272A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050919P 2014-09-16 2014-09-16
US62/050,919 2014-09-16

Publications (1)

Publication Number Publication Date
WO2016044272A1 true WO2016044272A1 (fr) 2016-03-24

Family

ID=54197126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/050179 WO2016044272A1 (fr) 2014-09-16 2015-09-15 Procédés de conservation de la force musculaire au cours d'une période d'inactivité musculaire par administration de bêta-hydroxy-bêta-méthylbutyrate et d'un extrait de thé vert

Country Status (1)

Country Link
WO (1) WO2016044272A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257839A1 (fr) * 2020-06-17 2021-12-23 Metabolic Technologies, LLC Compositions et procédés d'utilisation du beta-hydroxy-beta-méthylbutyrate (hmb) pour améliorer la masse musculaire, la résistance et la fonction musculaire sans exercice

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
WO2013053795A1 (fr) * 2011-10-11 2013-04-18 Nestec S.A. Accélération de récupération musculaire après une atrophie musculaire induite par une immobilisation
WO2014055905A1 (fr) * 2012-10-04 2014-04-10 Abbott Laboratories Méthodes d'amélioration de l'effet de l'egcg sur l'atténuation de la perte musculaire squelettique
WO2014099904A1 (fr) * 2012-12-17 2014-06-26 Abbott Laboratories Procédés pour améliorer la fonction motrice, améliorer les capacités fonctionnelles et réduire la faiblesse musculaire chez un sujet
WO2014144458A1 (fr) * 2013-03-15 2014-09-18 Abbott Laboratories Procédés de maintien et d'amélioration de la fonction musculaire
WO2014179526A1 (fr) * 2013-05-01 2014-11-06 Abbott Laboratories Procédé pour améliorer la régénération de muscles âgés
WO2015094772A1 (fr) * 2013-12-18 2015-06-25 Abbott Laboratories Procédés pour accroître la synthèse protéique de muscle squelettique à l'aide d'extrait de thé vert
WO2015094767A1 (fr) * 2013-12-18 2015-06-25 Abbott Laboratories Méthodes pour maintenir ou augmenter le poids corporel à l'aide d'extrait de thé vert décaféiné

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
WO2013053795A1 (fr) * 2011-10-11 2013-04-18 Nestec S.A. Accélération de récupération musculaire après une atrophie musculaire induite par une immobilisation
WO2014055905A1 (fr) * 2012-10-04 2014-04-10 Abbott Laboratories Méthodes d'amélioration de l'effet de l'egcg sur l'atténuation de la perte musculaire squelettique
WO2014099904A1 (fr) * 2012-12-17 2014-06-26 Abbott Laboratories Procédés pour améliorer la fonction motrice, améliorer les capacités fonctionnelles et réduire la faiblesse musculaire chez un sujet
WO2014144458A1 (fr) * 2013-03-15 2014-09-18 Abbott Laboratories Procédés de maintien et d'amélioration de la fonction musculaire
WO2014179526A1 (fr) * 2013-05-01 2014-11-06 Abbott Laboratories Procédé pour améliorer la régénération de muscles âgés
WO2015094772A1 (fr) * 2013-12-18 2015-06-25 Abbott Laboratories Procédés pour accroître la synthèse protéique de muscle squelettique à l'aide d'extrait de thé vert
WO2015094767A1 (fr) * 2013-12-18 2015-06-25 Abbott Laboratories Méthodes pour maintenir ou augmenter le poids corporel à l'aide d'extrait de thé vert décaféiné

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257839A1 (fr) * 2020-06-17 2021-12-23 Metabolic Technologies, LLC Compositions et procédés d'utilisation du beta-hydroxy-beta-méthylbutyrate (hmb) pour améliorer la masse musculaire, la résistance et la fonction musculaire sans exercice

Similar Documents

Publication Publication Date Title
US20160361291A1 (en) Methods for increasing skeletal muscle protein synthesis using green tea extract
JP5421956B2 (ja) ホエータンパク質組成物、方法及び使用
TWI673052B (zh) 使用人乳寡糖之用於調節炎症之營養調配物
EP2442673B1 (fr) Poudres nutritionelles comprenant du beta-hydroxy-beta-methylbutyrate seche par pulverisation
ES2572831T3 (es) Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
US20130337144A1 (en) Nutritional products comprising calcium hmb and conjugated linoleic acid
JP2016517438A (ja) 筋肉機能を維持し、改善する方法
JP2016520050A (ja) 老化筋肉再生の増強方法
EP2986163B1 (fr) Compositions nutritionnelles comprenant du bêta-hydroxy-bêta-méthylbutyrate de calcium, des phosphopeptides de caseine et des proteines
WO2015105981A2 (fr) Essentialité conditionnelle de hmb
JP5465834B2 (ja) 肝機能保護剤
US20210220301A1 (en) Pharmaceutical or Nutritional Combination Comprising Beta-Hydroxy-Betamethylbutyrate
TW201635920A (zh) 肌肉合成促進劑
WO2016163245A1 (fr) Activateur du métabolisme énergétique dans les cellules musculaires
WO2015094767A1 (fr) Méthodes pour maintenir ou augmenter le poids corporel à l'aide d'extrait de thé vert décaféiné
WO2015137387A1 (fr) Médicament d'amélioration musculaire
WO2016044272A1 (fr) Procédés de conservation de la force musculaire au cours d'une période d'inactivité musculaire par administration de bêta-hydroxy-bêta-méthylbutyrate et d'un extrait de thé vert
WO2016044167A1 (fr) Procédés d'accroissement de la force musculaire et de la mobilité chez des sujets subissant une inactivité physique significative à l'aide d'acide gamma-linolénique
WO2013170189A1 (fr) Combinaison de bêta-hydroxy-bêta-méthylbutyrate et de bêta-alanine destinée à augmenter le débit musculaire
JP7156639B2 (ja) レスベラトロール誘導体の新規用途
WO2018079573A1 (fr) Composition visant à améliorer la baisse de l'absorption dans le tractus digestif, et composition visant à stimuler l'absorption dans le tractus digestif
JP2021024838A (ja) 子における脳由来神経栄養因子の産生を促進させる組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15770762

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15770762

Country of ref document: EP

Kind code of ref document: A1